Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Irbesartan

FDA-approved product (tablet, oral), marketed as Avapro, Irbesartan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Irbesartan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Chronic renal failure syndrome
  • Diabetic nephropathy
  • Hypertension
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
FDA pharmacologic class
Angiotensin 2 Receptor Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Irbesartan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Irbesartan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease

    NCT07555054 · start 2026-05-21

    Registered record
    Registry ID
    NCT07555054
    Conditions
    Chronic Kidney Disease
    Interventions
    HS-10390; HS-10390; HS-10390; Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-05-21
    Completion
    2028-12-31
    Enrolment
    182

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionHS-10390; HS-10390; HS-10390; Irbesartan
    PhasePhase 2
    Registry statusNot yet recruiting

  • Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy

    NCT06660940 · start 2024-10

    Registered record
    Registry ID
    NCT06660940
    Conditions
    Diabetic Kidney Disease; Diabetic Retinopathy
    Interventions
    Keluoxin Capsules; Keluoxin Capsule Simulants; Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-10
    Completion
    2027-10
    Enrolment
    460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Kidney Disease; Diabetic Retinopathy
    InterventionKeluoxin Capsules; Keluoxin Capsule Simulants; Irbesartan
    PhasePhase 4
    Registry statusNot yet recruiting

  • Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization

    NCT05670028 · start 2023-06-04

    Registered record
    Registry ID
    NCT05670028
    Conditions
    Ischemic Stroke; Revascularization; Blood Pressure; Cerebrovascular Insufficiency; Cerebral Autoregulation; Individuation; Hemorrhagic Transformation Due to Acute Stroke
    Interventions
    Hypotensive Drugs and/or Vasoactive Drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-06-04
    Completion
    2026-06-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke; Revascularization; Blood Pressure; Cerebrovascular Insufficiency +3 more
    InterventionHypotensive Drugs and/or Vasoactive Drugs
    PhasePhase 2
    Registry statusUnknown

  • Low-dose Quadruple Combination Therapy in Patients With Hypertension

    NCT05377203 · start 2022-07-13

    Registered record
    Registry ID
    NCT05377203
    Conditions
    Hypertension; Arterial Hypertension
    Interventions
    Quadruple combination of half doses therapy→Dual combination of standard dose therapy; Dual combination of standard dose therapy→ Quadruple combination of half doses therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-07-13
    Completion
    2023-07-04
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Arterial Hypertension
    InterventionQuadruple combination of half doses therapy→Dual combination of standard dose therapy; Dual combination of standard dose therapy→ Quadruple combination of half doses therapy
    PhasePhase 4
    Registry statusCompleted

  • Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

    NCT04606563 · start 2020-10-09

    Registered record
    Registry ID
    NCT04606563
    Conditions
    Covid19; SARS-CoV Infection
    Interventions
    Losartan; Valsartan; Azilsartan; Candesartan; Eprosartan; Irbesartan; Olmesartan; Telmisartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-10-09
    Completion
    2022-04-22
    Enrolment
    341

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; SARS-CoV Infection
    InterventionLosartan; Valsartan; Azilsartan; Candesartan +4 more
    PhasePhase 3
    Registry statusTerminated

  • Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

    NCT04488978 · start 2020-05-21

    Registered record
    Registry ID
    NCT04488978
    Conditions
    Essential Hypertension
    Interventions
    Irbesartan/Amlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-05-21
    Completion
    2021-11-09
    Enrolment
    440

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionIrbesartan/Amlodipine
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate ALN-AGT01 in Patients With Hypertension

    NCT03934307 · start 2019-05-01

    Registered record
    Registry ID
    NCT03934307
    Conditions
    Hypertension
    Interventions
    ALN-AGT01; ALN-AGT01-Matching Placebo; Irbesartan; Irbesartan-Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-05-01
    Completion
    2023-01-04
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionALN-AGT01; ALN-AGT01-Matching Placebo; Irbesartan; Irbesartan-Matching Placebo
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects

    NCT05786339 · start 2018-11-17

    Registered record
    Registry ID
    NCT05786339
    Conditions
    Therapeutic Equivalency
    Interventions
    Tested Irbesartan Tablet; Reference Irbesartan Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-11-17
    Completion
    2019-05-15
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTherapeutic Equivalency
    InterventionTested Irbesartan Tablet; Reference Irbesartan Tablet
    PhasePhase 1
    Registry statusCompleted

  • Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan

    NCT03627715 · start 2018-11-06

    Registered record
    Registry ID
    NCT03627715
    Conditions
    Diabetic Kidney Disease
    Interventions
    Propagermanium; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-11-06
    Completion
    2020-08-18
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Kidney Disease
    InterventionPropagermanium; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.

    NCT03006796 · start 2017-01-16

    Registered record
    Registry ID
    NCT03006796
    Conditions
    Arterial Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-01-16
    Completion
    2020-03-31
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Bariatric Surgery and Pharmacokinetics of Irbesartan

    NCT03476603 · start 2016-11-02

    Registered record
    Registry ID
    NCT03476603
    Conditions
    Obesity, Morbid
    Interventions
    Irbesartan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2016-11-02
    Completion
    2026-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity, Morbid
    InterventionIrbesartan
    PhaseNot recorded
    Registry statusRecruiting

  • Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)

    NCT02597361 · start 2016-01

    Registered record
    Registry ID
    NCT02597361
    Conditions
    Ehlers-Danlos Syndrome, Vascular Type
    Interventions
    Irbesartan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01
    Completion
    2020-02-19
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEhlers-Danlos Syndrome, Vascular Type
    InterventionIrbesartan; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation

    NCT02502110 · start 2015-08

    Registered record
    Registry ID
    NCT02502110
    Conditions
    Paroxysmal Atrial Fibrillation
    Interventions
    rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-08
    Completion
    2019-06
    Enrolment
    346

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Atrial Fibrillation
    Interventionrosuvastatin
    PhasePhase 4
    Registry statusUnknown

  • Multiple Treatments for Ebola Virus Disease (EVD)

    NCT02380625 · start 2015-04

    Registered record
    Registry ID
    NCT02380625
    Conditions
    Ebola Virus Disease
    Interventions
    Azithromycin; Sunitinib and Erlotinib; Atorvastatin and Irbesartan; IV fluids and laboratory testing
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2016-03
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEbola Virus Disease
    InterventionAzithromycin; Sunitinib and Erlotinib; Atorvastatin and Irbesartan; IV fluids and laboratory testing
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans

    NCT02386293 · start 2014-04

    Registered record
    Registry ID
    NCT02386293
    Conditions
    Hypertension; Obesity; Stress, Psychological; Blood Pressure
    Interventions
    Irbesartan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-04
    Completion
    2019-11-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Obesity; Stress, Psychological; Blood Pressure
    InterventionIrbesartan; Placebo
    PhasePhase 2
    Registry statusUnknown